RCS - Physiomics PLC - Physiomics Awarded New Contract by GARDP

PhysiomicsAnnouncement

10/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251210:nRSJ8822Ka&default-theme=true

RNS Number : 8822K  Physiomics PLC  10 December 2025

10 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract by GARDP FOUNDATION

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a new contract in the
biometrics department with a new client, GARDP Foundation ("GARDP"). GARDP is
a not-for-profit research and development organisation that addresses global
public health needs by developing new or improved antibiotic treatments, while
endeavouring to ensure sustainable access.

In this project, Physiomics will provide expert consultancy support to GARDP
to optimise the design of an efficacy trial in their Serious Bacterial
Infections (SBIs) programme. The work for this project is expected to begin
January 2026 and is expected to complete within three months.

This project represents an important development in our Biometrics department,
being our second major client in this space. We will be providing our client
with a strategic partner to support their clinical development plans through
optimising design and lean on both the internal expertise at Physiomics, as
well as our network of consultants.

 

Jesse Thissen, Head of Biometrics at Physiomics, commented:

"We're delighted to start our new partnership with GARDP through this project.
Utilising our expertise in study design to support clinical development
planning aligns perfectly with our mission to help clients make faster, more
informed decisions that can help de-risk development and improve
outcomes. This project also marks further expansion into new therapeutic
areas for Physiomics in Infectious Disease, which has been a target for the
Company."

 

Dr Peter Sargent, CEO of Physiomics, commented:

"This contract award represents a significant milestone for our organisation.
Securing our third Biometrics contract since launching the new service line
earlier this summer has surpassed our initial projections and underscores the
promising contribution this service can make to the Company's growth
objectives."

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFVSFDLAIIE



            Copyright 2019 Regulatory News Service, all rights reserved